Sarcomas
Conditions
Brief summary
Toxicity will be classified according to the common toxicity criteria established by the National Cancer Institute (CTC NCI, version 5.0).
Detailed description
Incidence of episodes of febrile neutropenia, bacteraemia, infections (viral, fungal), haematological recovery and hospital admission associated with treatment., Five-year disease progression rate after treatment with NK cells + IL-2. This will be determined by imaging techniques., Expression levels of NK cell inhibitory/activating ligands in solid tumour samples and patient serum. These shall be determined by immunohistochemistry and PCR techniques.
Interventions
DRUGAllogeneic peripheral blood-derived CD56+ natural killer cells
DRUGco-cultured with K562-mb15-41BBI cell line
Sponsors
Hospital Universitario La Paz, Hospital Universitario La Paz
Eligibility
Sex/Gender
All
Age
0 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Toxicity will be classified according to the common toxicity criteria established by the National Cancer Institute (CTC NCI, version 5.0). | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of episodes of febrile neutropenia, bacteraemia, infections (viral, fungal), haematological recovery and hospital admission associated with treatment., Five-year disease progression rate after treatment with NK cells + IL-2. This will be determined by imaging techniques., Expression levels of NK cell inhibitory/activating ligands in solid tumour samples and patient serum. These shall be determined by immunohistochemistry and PCR techniques. | — |
Countries
Spain
Outcome results
None listed